Posted by Michael Wonder on 09 Mar 2019
Foamix announces FDA acceptance of new drug application for FMX101 minocycline foam for the treatment of moderate-to-severe acne
7 March 2019 - PDUFA target action date of 20 October 2019.
Foamix Pharmaceuticals today announced that the U.S. FDA has accepted for review the new drug application for FMX101.
Foamix is seeking approval of FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older.
